Bimekizumab-bkzx Therapeutic Cheat Sheet
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma …
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Intravenous immune globulin (IVIG) is a concentrate of pooled immunoglobulins derived from plasma donors. Its unique mechanism of action expands the utility of the medication to a variety of conditions. We continue our series, Therapeutic Cheat Sheet, with a closer look at IVIG, which is FDA-approved for the treatment of dermatologic conditions including dermatomyositis, Kawasaki disease, ITP, and … 
While we have an increasing armamentarium of biologic agents and targeted systemic medications for certain dermatologic conditions such as psoriasis or atopic dermatitis, treatment options are still limited for a litany of other inflammatory cutaneous disorders. Additionally, when discussing therapeutic options, patients often opt for medications that are established, safe, well-tolerated and mini … 
Thalidomide was introduced in the 1950s as a “safe” sleeping medication; however, it quickly became vilified and was removed from the market for its severe teratogenic effects, most commonly phecomelia, or loss of arms and legs. Despite these devastating birth defects, thalidomide has a variety of indications for dermatologic conditions, with manageable side effects when used appropriately. We … 
Hyperhidrosis affects up to 4.8% of people in the United States, causing significant impacts in patient quality of life.1 Often times, the etiology of symptoms cannot be identified, resulting in a subset of disease termed “primary hyperhidrosis.” Symptoms may be focal or generalized. Because there is a scarcity of FDA-approved treatments for primary hyperhidrosis, treatment often requires a mu … 